CoChat

Continuation Treatment of Chronic Depression: A Comparison of Nefazodone, Cognitive Behavioral Analysis System of Psychotherapy, and Their Combination

Kocsis, James H., MD, Rush, A. John, MD, Markowitz, John C., MD, Borian, Frances E., RN, MBA, Dunner, David L., MD, Koran, Lorrin M., MD, Klein, Daniel N., PhD, Trivedi, Madhukar H., MD, Arnow, Bruce, PhD, Keitner, Gabor, MD, Kornstein, Susan G., MD, Keller, and Martin B., MD · 2025 · Psychopharmacology Bulletin
Cited by 44

The DOI matches its Crossref record.

Abstract

Little is known about the relative benefits of psychotherapy, medication, and combined treatment as continuation therapies for chronic forms of major depressive disorder (MDD) after a positive response to acute treatment. We hypothesize that combined treatment would demonstrate superior continuation phase outcomes compared to either monotherapy, as evidenced by lower relapse rates and greater rates of improvement from partial to full remission. We report 16-week continuation phase outcomes for 324 patients who had participated in either the acute phase of a randomized multicenter trial of nefazodone, Cognitive Behavioral Analysis System of Psychotherapy (CBASP), or combination therapy (COMB) for chronic forms of MDD. Patients entering the continuation phase had either fully or partially remitted after 12 weeks of acute phase treatment. The primary

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.64719/pb.4164

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

Metadata

Authors
Kocsis, J. H., MD, Rush, A. J., MD, Markowitz, J. C., MD, Borian, F. E., RN, MBA, Dunner, D. L., MD, Koran, L. M., MD, Klein, D. N., PhD, Trivedi, M. H., MD, Arnow, B., PhD, Keitner, G., MD, Kornstein, S. G., MD, Keller, A. M. B., & MD
Venue
Psychopharmacology Bulletin
Published
2025-08-12
Volume
37
Issue
4
Pages
73-87
ISSN
  • 0048-5764 (ISSN-L)
  • 2472-2448
OpenAlex
W161610379
Cited by
44
References
0
FWCI
0.00
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.